Maverick Medical AI Announces Completion of The Implementation of Its Real-Time Autonomous Medical Coding Solution at RadNet




Maverick Medical AI Announces Completion of The Implementation of Its Real-Time Autonomous Medical Coding Solution at RadNet

Successful deployment achieved across all RadNet sites and 10 million medical reports processed to date

WILMINGTON, Del.–(BUSINESS WIRE)–Maverick Medical AI announced today the completion of a successful deployment of its real-time autonomous AI-powered medical coding solution across all 399 sites of RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services.

RadNet integrated Maverick Medical AI’s mCoder solution to automate the medical coding process. Using deep learning and synthetic data generation, mCoder analyzes reports to accurately generate reimbursement codes in real-time. RadNet has successfully processed more than 10 million reports using Maverick’s technology to date.

“When medical coding is performed in real-time, it helps us improve revenue cycle efficiency. Maverick’s solution enables us to reduce errors, avoid billing backlogs, and ease the administrative burden on our radiologists. Maverick’s medical coding is delivered to our systems in seconds,” said Susan Hollabaugh, RadNet’s senior vice-president of I.T.

In the near future, RadNet intends to implement the recently launched Maverick CodePilot™ into radiologists’ reporting workflow, providing an interactive real-time interface for radiologists. Once integrated, Radiologists will be able to resolve coding-related omissions before signing their reports, thereby reducing the need for addenda and manual follow-up with radiologists which often result in billing delays.

“Our implementation of Maverick’s solutions has resulted in a significant increase in our direct-to-bill rate, a testament to this technology’s effectiveness,” adds Hollabaugh. “We look forward to providing our radiologists with real-time coding assistance, reducing the need for coding-related addenda.”

“RadNet is the country’s largest outpatient imaging provider, and our solutions enable RadNet to harness deep learning and AI capabilities in medical coding to realize significant operational improvements. From radiologist workflow to revenue cycle operations, our real-time autonomous coding solution delivers benefits across the enterprise. We look forward to further collaboration,” said Maverick AI CEO Yossi Shahak.

About Maverick Medical AI

Maverick Medical AI revolutionizes medical coding for healthcare providers with its AI-powered real-time Autonomous Medical Coding platform. By combining in-depth knowledge of medical coding with advanced large language models and deep learning technologies, Maverick’s platform autonomously analyzes clinical notes and reports to generate accurate medical codes.

We overcome revenue cycle challenges by seamlessly integrating Medical Coding operations with Point-of-Care in real-time to optimize reimbursement. Maverick significantly surpasses industry standards with an 85% Direct-to-Bill rate, automating the medical coding process to enhance efficiency, reduce the workload on human coders, and minimize errors. This automation ensures a smoother, more reliable, and consistent revenue cycle process for healthcare providers.

For more information, visit: www.maverick-ai.com/

About RadNet

RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com.

Contacts

Michael Wong | VP Marketing

MAVERICK MEDICAL AI

M|  416-723-6843

W|  http://www.maverick-ai.com/

BioTalent Canada Honoured at 2024 Best Ottawa Business Awards as Best Leader in Diversity, Equity and Inclusion




BioTalent Canada Honoured at 2024 Best Ottawa Business Awards as Best Leader in Diversity, Equity and Inclusion

OTTAWA, Ontario–(BUSINESS WIRE)–#ait–BioTalent Canada is thrilled to announce its recognition as the Best Leader in Diversity, Equity, and Inclusion (DEI) at the 2024 Best Ottawa Business Awards (BOBs). This honour celebrates organizations that lead by example, foster inclusive workplaces, and advance equitable opportunities in their industries. The national not-for-profit workforce development council is headquartered in Ottawa.

“At BioTalent Canada, we feel diversity, equity and inclusion are not just ideals; they are now part of our DNA,” says Rob Henderson, President and CEO of BioTalent Canada. “This award speaks to our ongoing efforts to create an environment where individuals can thrive and be heard. We endeavour to practice what we preach: a bio-economy that truly reflects the rich diversity of Canada.”

BioTalent Canada’s integration of IDEAL (inclusion, diversity, equity and accessibility leadership) principles into its business strategy has transformed its culture and operations. Recent initiatives include:

• Establishing an IDEA Committee: an employee-led group that guides team education initiatives and celebrations throughout the year and ensures that inclusivity, equity, diversity, and accessibility are embedded throughout the organization.
• Cultivating an Inclusive Workplace: Through open forums and conversations sparked by employees’ lived experiences of systemic racism, and a commitment to transparency and equity in hiring, BioTalent Canada wants to foster a culture of respect and belonging.
• Supports Creating Diverse Talent Beyond the Organization: IDEA is the backdrop of its National Talent Strategy to ensure Canada’s bio-economy builds a strong workforce. All BioTalent Canada’s programs contain an IDEA component including:
  • The I.D.E.A.L. Bioscience Employer^™ program helps employers showcase their commitment to IDEA leadership and attract diverse talent.
  • The I.D.E.A.L. Bioscience Scholarship^™ program, established in 2024, empowers and propels individuals from equity-deserving groups who are IDEA leaders to pursue science, technology, engineering, and mathematics (STEM) education.
  • Practical employer resources to help create a diverse workforce through topics such as hiring persons with disabilities and internationally educated professionals; and adopting inclusion, diversity, equity and accessibility in the workplace.

“This award is a recognition of past and current efforts; it’s a call to action for SMEs in our industry,” adds Henderson. “With the bio-economy needing 65,000 skilled workers by 2029, we have an opportunity—and a responsibility—to create pathways for equity-deserving talent. Inclusion is not just ethical; it’s essential for our industry’s growth and innovation.”

The company’s recent Employee Engagement Survey results underscore BioTalent Canada’s progress:

• 97% of employees believe diversity of people and opinions is valued at BioTalent Canada.
• 95% feel the workplace is inclusive, treating people equally regardless of race, ethnicity, gender, or sexual orientation.

With distinctions in 2024, including Magnet Network’s 2024 Collaboration Catalyst award, 5-Star DEI Employer designation by Canadian HR Reporter and recognition as one of Canada’s Great Places to Work, BioTalent Canada is trying to set a standard for a sustainable and inclusive bio-economy as one of its SMEs.

Rob Henderson is available for comment.

About BioTalent Canada

BioTalent Canada supports the people behind life-changing science. Trusted as the go-to source for labour market intelligence, BioTalent Canada guides bio-economy stakeholders with evidence-based data and industry-driven standards. BioTalent Canada, as a workforce development council, is focused on igniting the industry’s brainpower, bridging the gap between job-ready talent and employers, and ensuring the long-term agility, resiliency, and sustainability of one of Canada’s most vital sectors.

Recently named a Great Place to Work^® for 2024 and Best Workplaces in Healthcare for 2023, by Great Place to Work Canada^®, as well as being listed as a Best Workplace by HRD Canada for 2024, a 5-Star Diversity, Equity and Inclusion Employer by Canadian HR Reporter for 2024 and a 2024 Collaboration Catalyst by Magnet Network, BioTalent Canada practices the same industry standards it recommends to stakeholders. These varied distinctions were awarded to BioTalent Canada following a thorough and independent analysis of the organization.

For more information, please visit biotalent.ca.

Contacts

Media Inquiries:
Siobhan Williams

Vice-President Marketing and Communications

BioTalent Canada

613-235-1402 ext. 229

swilliams@biotalent.ca

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)




Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 29, 2024.

One individual was hired by Adicet in November 2024 and granted new hire non-qualified stock options to purchase 6,000 shares of Adicet’s common stock with an exercise price of $1.13 per share, the closing price of Adicet’s common stock as reported by Nasdaq on November 29, 2024. One-fourth of the shares underlying the employee’s option will vest on the one-year anniversary of the recipient’s start date and thereafter the remaining three-fourths of the shares underlying the employee’s option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to the employee will be fully vested on the fourth anniversary of the recipient’s start date, subject to the employee’s continued employment with Adicet on such vesting dates.

The above-described award was granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The award was authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Adicet Bio, Inc.
Investor and Media Contacts

Investors:
Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Precision AQ

212-362-1200

janhavi.mohite@precisionaq.com

Media:
Kerry Beth Daly

kbdaly@adicetbio.com

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)




Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 29, 2024.

One individual was hired by Adicet in November 2024 and granted new hire non-qualified stock options to purchase 6,000 shares of Adicet’s common stock with an exercise price of $1.13 per share, the closing price of Adicet’s common stock as reported by Nasdaq on November 29, 2024. One-fourth of the shares underlying the employee’s option will vest on the one-year anniversary of the recipient’s start date and thereafter the remaining three-fourths of the shares underlying the employee’s option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to the employee will be fully vested on the fourth anniversary of the recipient’s start date, subject to the employee’s continued employment with Adicet on such vesting dates.

The above-described award was granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The award was authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Adicet Bio, Inc.
Investor and Media Contacts

Investors:
Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Precision AQ

212-362-1200

janhavi.mohite@precisionaq.com

Media:
Kerry Beth Daly

kbdaly@adicetbio.com

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)




Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 14 individuals hired by Sarepta in November 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received in the aggregate 8,040 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta’s common stock.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Contacts

Investor Contact:
Ian Estepan, 617-274-4052

iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566

tsorrentino@sarepta.com

Generic Injectables Global Strategic Business Report 2024-2030: Upcoming Patent Expirations of Key Branded Injectable Drugs as a Cost-Effective Alternative, Opening Up New Market Opportunities – ResearchAndMarkets.com




Generic Injectables Global Strategic Business Report 2024-2030: Upcoming Patent Expirations of Key Branded Injectable Drugs as a Cost-Effective Alternative, Opening Up New Market Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Generic Injectables – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.

The global market for Generic Injectables was estimated at US$95.2 Billion in 2023 and is projected to reach US$206.8 Billion by 2030, growing at a CAGR of 11.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

One of the primary drivers is the increasing incidence of chronic diseases globally, which has led to a heightened demand for injectable therapies. Conditions such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders often require long-term or rapid-response treatments, and injectables are a preferred delivery method in these cases due to their fast-acting nature. As chronic diseases rise, especially in aging populations, the demand for affordable injectable medications continues to grow.

Another significant driver is the advancement in biologics and biosimilars, which has expanded the range of complex injectables available in the market. As more biologic patents expire, opportunities for the introduction of biosimilar injectables increase, providing a lower-cost alternative to expensive branded biologics. Moreover, technological innovations in drug delivery systems, such as the development of prefilled syringes and autoinjectors, have made injectables more accessible to patients.

These innovations support the trend towards home-based care and self-administration, reducing the burden on healthcare facilities. The global shift towards cost-effective healthcare solutions, combined with government initiatives to increase the use of generics, has further boosted the demand for generic injectables.

Why Are Generic Injectables Gaining Such Immense Popularity Across the Globe?

Generic injectables have emerged as a vital component of modern healthcare systems, offering cost-effective alternatives to branded drugs while maintaining the same efficacy and safety standards. With the increasing burden of chronic diseases like cancer, cardiovascular disorders, and diabetes, the demand for injectables has soared, particularly for treatments requiring quick, potent delivery. Generic injectables, being lower-priced versions of branded injectables, allow healthcare systems to treat more patients efficiently without compromising quality. Hospitals, clinics, and emergency care centers have increasingly integrated these generics into their treatment protocols to manage both acute and chronic conditions. The ability to quickly administer life-saving drugs, particularly in critical care settings, has made generic injectables indispensable, with their global demand continuing to grow year on year.

Furthermore, advancements in drug delivery systems, including prefilled syringes and ready-to-use vials, have bolstered the adoption of generic injectables across various healthcare settings. Prefilled syringes and other single-use formats provide an extra layer of safety by minimizing contamination risks and ensuring accurate dosing.

With their increasing availability in oncology, anesthesia, anti-infective drugs, and immunotherapy, the role of generic injectables in both treatment and prevention is expanding. Their ability to provide cost savings to healthcare providers while ensuring that patient outcomes are not compromised is a major reason for their accelerated adoption.

What Role Do Technological Innovations Play in Expanding the Generic Injectables Market?

Technological advancements have played a transformative role in driving the growth of the generic injectables market. Improvements in manufacturing technologies, such as continuous production and advanced sterilization processes, have increased the efficiency and scalability of generic injectables production. These innovations have reduced manufacturing costs while ensuring that production meets stringent regulatory standards. Additionally, advancements in biotechnology have enabled the development of complex generic injectables, including biosimilars, which are increasingly used to treat autoimmune diseases and various cancers. The growing use of biologics in modern medicine has opened up new opportunities for generic injectables manufacturers to provide lower-cost alternatives in this high-demand segment.

The rise of automation and robotics in injectable production is also a critical factor. Automated systems improve precision in production, reduce human errors, and streamline the manufacturing process, making it easier for pharmaceutical companies to meet global demand. Furthermore, advances in packaging technologies, such as prefilled syringes and autoinjectors, make injectables more user-friendly, facilitating home care administration and reducing hospital visits. As healthcare shifts towards more patient-centered models, the development of self-administrable injectables is gaining traction, contributing to the expansion of the market.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players in the Global Generic Injectables Market such as American Regent, Inc., Ascendia Pharmaceuticals, Aurobindo Pharma Ltd., Baxter International, Inc., Biocon Ltd. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Vials segment, which is expected to reach US$109.9 Billion by 2030 with a CAGR of a 12.7%. The Ampoules segment is also set to grow at 11.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $20.0 Billion in 2023, and China, forecasted to grow at an impressive 15.0% CAGR to reach $43.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Key Attributes:

Key Topics Covered:

MARKET OVERVIEW

• Efficacy and Cost Benefits Continue to Drive Growth in Global Generic Injectables Market
• Global Economic Outlook
• Generic Injectables – Global Key Competitors Percentage Market Share in 2024 (E)
• Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• Generic Injectables: Product Overview
• Recent Market Activity
• Influencer/Product/Technology Insights

MARKET TRENDS & DRIVERS

• A Look into Growing Shift Towards Injectables
• Complex Injectables and Small-Volume Parenterals: A Challenging but High-Value Market
• Upcoming Patent Expirations of Key Branded Injectable Drugs Throw the Spotlight on Generics as a Cost-Effective Alternative, Opening Up New Market Opportunities
• Increasing Demand for Cost-Effective Healthcare Solutions Propels Significant Growth in the Generic Injectables Market
• Regulatory Incentives and Fast-Track Approvals for Biosimilars Strengthen the Business Case for Expanding Generic Injectable Offerings
• Expanding Geriatric Population and Rising Incidence of Age-Related Diseases Drive Strong Adoption of Generic Injectable Medications
• Technological Advancements in Injectable Drug Delivery Systems, Including Prefilled Syringes and Auto-Injectors, Sustain Long-Term Growth of Generic Injectables
• Surge in the Prevalence of Chronic Diseases, Such as Diabetes and Cardiovascular Disorders, Spurs Increased Demand for Generic Injectable Treatment Options
• Rise in Incidence of Cancer and Associated High Treatment Costs Drives Demand for Generic Injectable Treatments
• Growing Availability of Complex Biologics and Biosimilars Expands the Addressable Market Opportunity for Generic Injectables, Increasing Market Penetration
• Growing Preference for Home-Based Healthcare Services and Self-Administration Drives Demand for Generic Injectable Auto-Injectors and Other Patient-Friendly Solutions
• Rise of Infectious Diseases Drive Demand for Injectables
• Long-Term Mental Health Management Drives Growth Prospects
• Rising Demand for Affordable Alternatives to Branded Injectable Drugs
• Growth in Healthcare Expenditure Driving Demand for Cost-Effective Treatments
• Increasing Adoption of Generic Injectables in Hospitals and Ambulatory Settings
• Expansion of Generic Injectable Offerings in Oncology and Chronic Disease Management
• Surge in Demand for Injectable Antibiotics and Critical Care Medications
• Technological Advancements in Injectable Formulations for Improved Efficacy
• Growth in Outsourcing Injectable Manufacturing to Reduce Production Costs
• Expansion of Generic Injectables in Emerging Markets with Expanding Healthcare Access
• Increased Focus on Biologics and Biosimilar Injectable Products
• Rising Adoption of Pre-Filled Syringes and Auto-Injectors in Drug Delivery
• Development of Generic Injectables to Address Supply Shortages of Critical Medications
• Growth in Research and Development of Complex Injectables

FOCUS ON SELECT PLAYERS: Some of the 43 companies featured in this Global Generic Injectables market report include

• American Regent, Inc.
• Ascendia Pharmaceuticals
• Aurobindo Pharma Ltd.
• Baxter International, Inc.
• Biocon Ltd.
• Biological E. Ltd.
• Bristol-Myers Squibb Company
• Cipla Ltd.
• Cosette Pharmaceuticals, Inc.
• Dr. Reddy’s Laboratories Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/h7y985

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Devonian Reports Its Annual 2024 Financial Results




Devonian Reports Its Annual 2024 Financial Results

• Fourth quarter revenues of $9 Million increased 749% year over year
• Annual revenues of $17.8 Million increased 660% year over year
• Fourth quarter net income of $0.007 per share
• Annual net loss of $0.008 per share

QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces, as of November 28, 2024, financial results for its fiscal year ended July 31, 2024.

Management Comments

“This has been a breakout year for Devonian,” said Luc Grégoire, President and Chief Executive Officer of Devonian. “While continuing our scientific activities for the continued development of Thykamine^TM as a multi-target anti-inflammatory platform, including atopic dermatitis (eczema), our fourth quarter was highlighted by a 749% revenue growth at Altius, providing significant financial support to our ongoing operations.”

Business Highlights

• Altius Health Care Inc. (“Altius”), the Corporation’s wholly owned subsidiary, saw a significant uptake on its recently launched DEXLANSOPRAZOLE, the only authorized generic in the Canadian market for the treatment of gastroesophageal reflux disease (GERD).
• The Corporation continued to make progress in a number of pre-clinical studies on the impact of Thykamine^TM on a number of inflammation biomarkers, as well as continued its preparation for its planned phase II/III clinical study for Thykamine^TM in the treatment of mild to moderate atopic dermatitis (eczema) in pediatric patients, including preparatory work in the batch qualifications of the product to be used in the Corporation’s clinical studies.

Financial Highlights

• Distribution revenue for the fourth quarter was $9 million, up 749% year on year, driven by the DEXLANSOPRAZOLE launch. For the fiscal year ended July 31, 2024, distribution revenue was $17.82 million, up 660% year over year.
• Net income for the fourth quarter was $1.081 million, or $0.007 earnings per share, improving against the year-ago quarterly loss of $0.863 million, or $0.01 loss per share. For the fiscal year ended July 31, 2024, net loss was $1.225 million or $0.008 per share, as compared to a $4.600 million net loss, or $0.03 per share for the same period last year.
• Cash as of July 31, 2024, was $9.9 million, with debt of $2.08 million, as compared to cash of $5.1 million and debt of $3.6 million at the beginning of the fiscal year.

The consolidated financial statements for the fiscal years ended July 31, 2024 and 2023 (the “Financial Statements”), as well as the management & discussion analysis, are available under the Corporation’s profile on SEDAR+ at www.sedarplus.ca and on the Corporation’s website at: https://groupedevonian.com/investor-center/financial-reports/.

About Devonian

Devonian a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a United States FDA set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius, focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Devonian was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com

About Altius

Altius is a generic pharmaceutical distribution company with a primary focus of acquiring and in-licensing safe and innovative medicines and healthcare products designed to help people of all ages live healthier lives. Altius then leverages its expertise in the commercialization activities required to successfully launch and distribute these medicines in Canada.

For more information, visit www.altiushealthcare.ca

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the impact of proposed optimizations at the Corporations’ projects, global liquidity and credit availability on the timing of cash flows and the values of assets and liabilities based on projected future conditions, changes in accounting policies, the impact of inflation, the PCT patents for Thykamine^TM might not be granted, and, generally, the above “About Devonian” and “About Altius” paragraphs, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts

Devonian Health Group Inc.

Mr. Luc Grégoire

President and Chief Executive Officer

Telephone: 1 (450) 979-2916

E-mail: investors@groupedevonian.com

Renmark Financial Communications Inc.

Ben Ozerkevich: bozerkevich@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680

www.renmarkfinancial.com

Laser Photonics Launches R&D Initiative to Accelerate Innovation




Laser Photonics Launches R&D Initiative to Accelerate Innovation

ORLANDO, Fla.–(BUSINESS WIRE)–Laser Photonics Corporation (NASDAQ: LASE) (“LPC”), a leading global developer of industrial laser systems for cleaning and other material processing applications, announced today that it has launched a research and development initiative targeting industrial laser solutions for pharmaceutical tablet drilling, wafer scribing, and semiconductor marking.

Following LPC’s recent acquisition of Control Micro Systems, Inc., the company is dedicating resources to a number of new engineering projects to continue advancing its newly acquired laser systems. This investment of time and expertise, leveraging the innovative technologies and know-how from Control Micro Systems (“CMS”), aims to expand LPC’s footprint in diversified markets.

“Laser technology has reformed material processing across numerous industries,” said Wayne Tupuola, CEO of LPC. “We’re now tapping into more of these market segments with the addition of Control Micro Systems. Its state-of-the-art technology and Orlando-based development team have already proven invaluable.”

New sectors of focus are pharmaceuticals, wafers, and semiconductors. Through the R&D initiative the company will be devoting additional resources to advance its currently available technology to maintain a competitive edge and meet the needs of the market. In the pharmaceutical space, LPC will further develop Control Micro Systems tablet drilling and marking system for time-release medications. This Class I automated CO2 laser system features a custom tablet fixture, fume extraction, and machine vision inspection for quality control, engineered as an anti-counterfeiting solution.

Laser technology for wafer serialization entails the marking, scribing, and lapping of wafers composed of silicon and related compounds. LPC will continue to advance Control Micro Systems multi-station system, which is tailored for wafers up to 300 mm wide and 300 – 800 microns in thickness and features robotic wafer positioning. This technology serves to facilitate the production and tracking of wafers for consumer electronics, solar panels, LEDs, MEMS devices, optoelectronic components, and others.

The third system LPC will continue advancing through this initiative is the semiconductor laser marking system by CMS. This system is engineered with a high-precision ultraviolet laser and a galvanometer scanhead, enabling fast fiducial recognition. This innovative technology produces small permanent markings on IC mold compounds and ceramics with minimal heat, ensuring no damage to the part. Machine vision aids in the verification of chip positioning and marking alignment.

Stay tuned for LPC’s forthcoming announcements, where the company will reveal more details about each system.

About Laser Photonics Corporation

Laser Photonics is a vertically integrated manufacturer and R&D Center of Excellence for industrial laser technologies and systems. Laser Photonics seeks to disrupt the $46 billion, centuries-old sand and abrasives blasting markets, focusing on surface cleaning, rust removal, corrosion control, de-painting and other laser-based industrial applications. Laser Photonics’ new generation of leading-edge laser blasting technologies and equipment also addresses the numerous health, safety, environmental and regulatory issues associated with old methods. As a result, Laser Photonics has quickly gained a reputation as an industry leader in industrial laser systems with a brand that stands for quality, technology and product innovation. Currently, world-renowned and Fortune 1000 manufacturers in the aerospace, automotive, defense, energy, maritime, nuclear and space industries are using Laser Photonics’ “unique-to-industry” systems. For more information, visit https://www.laserphotonics.com.

Cautionary Note Concerning Forward-Looking Statements

This press release contains “forward-looking statements” (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended), including statements regarding the Company’s plans, prospects, potential results and use of proceeds. These statements are based on current expectations as of the date of this press release and involve a number of risks and uncertainties, which may cause results and uses of proceeds to differ materially from those indicated by these forward-looking statements. These risks include, without limitation, those described under the caption “Risk Factors” in the Registration Statement. Any reader of this press release is cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release except as required by applicable laws or regulations.

Contacts

Karla Kizzort

Marketing Specialist

Laser Photonics Corporation

kkizzort@laserphotonics.com

‘It’s Not Over’ until AIDS is Defeated: AHF UK Marks World AIDS Day




‘It’s Not Over’ until AIDS is Defeated: AHF UK Marks World AIDS Day

CROYDON, England–(BUSINESS WIRE)–#AIDS–In recognition of World AIDS Day (WAD) 2024 on 1 December, AHF UK will host a commemorative event at Croydon University Hospital (530 London Road, Thornton Heath, Surrey, CR7 7YE) on Monday, 2 December 2024, at 9:30 a.m. – 3:00 p.m. to raise awareness that “It’s Not Over” in the fight against HIV/AIDS. The event aims to raise awareness, promote prevention, testing, and treatment, and support all those affected by HIV/AIDS in the UK and globally.

Despite decades of progress, around 40 million people globally are living with HIV, more than half of whom are women and girls, with approximately 1.3 million new infections reported each year, according to UNAIDS. Stigma and discrimination continue to keep individuals from seeking essential care, and many key populations face substantial barriers to accessing treatment. This World AIDS Day event will spotlight these challenges, emphasizing the need to keep HIV/AIDS a priority on national and global public health agendas.

AHF UK’s World AIDS Day 2024: On 2 December, AHF UK will celebrate WAD with Croydon NHS Trust and partners at Croydon University Hospital. The event is aimed at raising awareness about HIV/AIDS and promoting the importance of testing. There will be free HIV/STI testing, a knowledge quiz with incentive freebies, and free condom packs and information for participants.

NEWS DESK NOTE & VISUALS: WAD Balloons, freebies, condom packs and banners.

“Effective treatment enables people living with HIV to maintain good health and ensures they cannot pass on the virus. However, in 2023, 40% of the 2,810 new diagnoses in England were made late—when their immune systems were already significantly weakened, and earlier treatment would have been beneficial. This highlights the need to prioritise HIV and sexual health as integral parts of our health and wellbeing agendas,” said Beatrice Nabulya, Testing and Volunteer Lead at AHF UK. “We must leverage the strong community structures we have locally and nationally to address HIV stigma and expand access to education, awareness, testing, treatment, and prevention services. World AIDS Day is a moment to reaffirm our commitment through collective community action. Progress has been made, but ‘It’s Not Over’ until stigma is eradicated, everyone has access to testing, and anyone who tests positive is linked to life-saving treatment.”

“Europe faces a unique challenge as we see a stagnation in the HIV response, particularly in Eastern Europe, where new cases continue to rise. We must reinvigorate our public health strategies to prevent new HIV infections and ensure our health systems are adequately funded to support accessible testing, treatment, and stigma reduction efforts,” added AHF Europe Bureau Chief Daniel Reijer. “On this World AIDS Day, let’s unite in our efforts to advocate for a renewed commitment to ending the HIV epidemic—because ‘It’s Not Over’ until we achieve it.”

World AIDS Day serves as a vital platform for HIV/AIDS advocates to acknowledge the progress made, remember those we have lost to AIDS-related illnesses and those who carry on the fight, and call on governments worldwide to commit the necessary resources and political support to end HIV/AIDS. On this World AIDS Day, we’re reminded: It’s Not Over.

AIDS Healthcare Foundation (AHF) is a global non-profit organization providing cutting-edge medicine and advocacy to over 2 million people in 48 countries worldwide in Africa, the Americas, the Asia/Pacific Region, and Europe. We are currently the largest non-profit provider of HIV/AIDS medical care in the world. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare.

Contacts

UK MEDIA CONTACT:

Beatrice Nabulya, Testing and Volunteer Lead, AHF UK

+44 7836 745837

Beatrice.Nabulya@ahf.org

US MEDIA CONTACT:

Ged Kenslea, Senior Director, Communications, AHF

+1 323.308.1833 work +1.323.791.5526 mobile

gedk@aidshealth.org

Denys Nazarov, Director of Global Policy & Communications, AHF

+1 323.308.1829

denys.nazarov@aidshealth.org

CORRECTING and REPLACING Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity




CORRECTING and REPLACING Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity

LAVAL, Québec–(BUSINESS WIRE)–#Altasciences–Please replace the release dated November 21, 2024 with the following corrected version due to multiple revisions.

The updated release reads:

ALTASCIENCES SUPPORTS METSERA IN THEIR EARLY-STAGE CLINICAL TRIALS FOR OBESITY

Altasciences is proud to have supported Metsera, Inc., a clinical stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, on its nonclinical and early-stage clinical trials. This support includes a recent Phase I/II trial of MET-097i, an ultra-long-acting injectable, fully biased GLP-1 receptor agonist.

In September, Metsera reported positive topline results from the clinical trial conducted at Altasciences’ facility, in which MET-097i demonstrated a 7.5% reduction in body weight from baseline at day 36 (one week after the final dose) and a 380-hour half-life. This work enabled Metsera to recently initiate a randomized 16-week Phase II trial of MET-097i.

In addition to clinical conduct, Altasciences supported Metsera with its Proactive Drug Development solution, including nonclinical, bioanalysis, CRO and program management services for several additional therapeutic candidates. Over the past six months, Altasciences has completed nonclinical work for MET-233i, an ultra-long-acting injectable amylin analog, as well as MET-002, an oral GLP-1 receptor agonist peptide, which has proven instrumental in allowing Metsera to begin clinical trials for both programs this year.

“Congratulations to Metsera on reaching this significant milestone in the development of MET-097i,” said Ingrid Holmes, Vice President of Global Clinical Operations at Altasciences. “Metsera is a highly valued partner of Altasciences, and we are proud to have contributed to this program aimed at helping individuals struggling with obesity-related illnesses.”

Obesity impacts millions of people worldwide and is a driver of serious health risks, including type 2 diabetes, heart disease, and certain cancers. Innovative treatments, like MET-097i, could offer potential new treatment options for those affected by this complex condition.

About Altasciences

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.

Contacts

Julie-Ann Cabana

Altasciences
jcabana@altasciences.com